[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ardelyx Inc (ARDX)

Ardelyx Inc (ARDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,790,303
  • Shares Outstanding, K 245,247
  • Annual Sales, $ 407,320 K
  • Annual Income, $ -61,600 K
  • EBIT $ -37 M
  • EBITDA $ -34 M
  • 60-Month Beta 0.62
  • Price/Sales 4.14
  • Price/Cash Flow N/A
  • Price/Book 11.35

Options Overview Details

View History
  • Implied Volatility 87.02% (-5.18%)
  • Historical Volatility 48.59%
  • IV Percentile 76%
  • IV Rank 39.06%
  • IV High 151.31% on 02/06/26
  • IV Low 45.81% on 08/21/25
  • Expected Move (DTE 10) 0.82 (11.56%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 4,172
  • Volume Avg (30-Day) 3,098
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 76,266
  • Open Int (30-Day) 51,376
  • Expected Range 6.31 to 7.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.02
  • Number of Estimates 6
  • High Estimate $0.01
  • Low Estimate $-0.06
  • Prior Year $-0.08
  • Growth Rate Est. (year over year) +75.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.73 +24.43%
on 04/07/26
7.43 -4.04%
on 05/05/26
+1.19 (+20.03%)
since 04/02/26
3-Month
5.11 +39.67%
on 03/24/26
7.43 -4.04%
on 05/05/26
+0.13 (+1.86%)
since 02/05/26
52-Week
3.21 +122.12%
on 05/15/25
8.40 -15.12%
on 01/23/26
+3.40 (+90.90%)
since 05/05/25

Most Recent Stories

More News
Ardelyx: Q1 Earnings Snapshot

Ardelyx: Q1 Earnings Snapshot

ARDX : 7.13 (-2.33%)
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update

Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year IBSRELA Q1 2026 revenue growth of 58% year-over-year to $70.1 million; Reiterating guidance of $410-$430 million...

ARDX : 7.13 (-2.33%)
Ardelyx Earnings May Confirm Whether IBSRELA's Growth Trajectory Is Real or Rhetorical

Barchart Research What to Expect from ARDX Earnings ARDX Generated April 29, 2026 Current Price $6.01 EPS Estimate $$-0.13 Consensus Rating Strong Buy Average Move 18.26% Ardelyx Earnings May Confirm Whether...

ARDX : 7.13 (-2.33%)
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings

WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines...

ARDX : 7.13 (-2.33%)
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines...

ARDX : 7.13 (-2.33%)
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant...

ARDX : 7.13 (-2.33%)
BMY : 56.95 (-0.75%)
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization...

ARDX : 7.13 (-2.33%)
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant...

ARDX : 7.13 (-2.33%)
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines...

ARDX : 7.13 (-2.33%)
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant...

ARDX : 7.13 (-2.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase...

See More

Key Turning Points

3rd Resistance Point 7.88
2nd Resistance Point 7.66
1st Resistance Point 7.39
Last Price 7.13
1st Support Level 6.90
2nd Support Level 6.68
3rd Support Level 6.41

See More

52-Week High 8.40
Last Price 7.13
Fibonacci 61.8% 6.42
Fibonacci 50% 5.80
Fibonacci 38.2% 5.19
52-Week Low 3.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.